Results 11 to 20 of about 9,231 (199)

Targeted Therapy of Myelofibrosis [PDF]

Клиническая онкогематология, 2017
Background. Myelofibrosis (primary myelofibrosis, post-essential trombocythemia myelofibrosis, post-polycythemia myelofibrosis) is the most complex and pressing problem among all Ph-negative myeloproliferative diseases. The present article summarizes the
Ol’ga Yur’evna Vinogradova, V. A. Shuvaev, I. S. Martynkevich, M. M. Pankrashkina, M. S. Fominykh, E. V. Efremova, K. Yu. Krutikova, L. B. Polushkina, N. N. Sharkunov, S. V. Voloshin, A. V. Chechetkin   +10 more
doaj   +2 more sources

Osteolytic lesions in myelofibrosis

Clinical Case Reports, 2021
Bony pain in patients with a history of myelofibrosis warrants further investigation. Although skeletal involvement in myelofibrosis is more commonly osteosclerosis or periostitis, it can also cause osteolytic lesions.
Isla Johnson, Hassan Alkhateeb
doaj   +2 more sources

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse

Clinical Case Reports, 2023
Key Clinical Message Here, we describe a patient with post‐transplant myelofibrosis with chronic graft‐versus‐host disease (GVHD), who showed successful molecular remission with ropeginterferon with 100% donor chimerism without any flare up of GVHD.
Barnali Srivastava, Christine Wolschke, Nico Gagelmann, Anita Badbaran, Nicolaus Kröger   +4 more
doaj   +2 more sources

CLINICAL AND PATHOMORPHOLOGICAL EXAMINATION OF MYELOFIBROSIS IN CHRONIC MYELOID LEUKEMIA

Сибирский онкологический журнал, 2016
Pathomorphology study of marrow fibrosis in patients with chronic myeloid leukemia was carried out using morphometric image analysis software. It was revealed that every second patient had myelofibrosis.
T. Yu. Dolgikh, I. V. Kachesov, A. A. Marchenko, N. P. Domnikova   +3 more
doaj   +1 more source

Severe tophaceous gout in the setting of myelofibrosis: A clinical challenge

Radiology Case Reports
We illustrate a case of a patient with a history of myelofibrosis, presenting with a clinical picture of presumed infection. Imaging revealed apparent fluid collections and erosions in the ankle/foot, supporting the clinical suspicion of infection ...
Nicole Chin, BA, Aidan Megally, MA, Omar Zahra, BS, Akshita Gorantla, BS, Shravika Talla, MD, Emad Allam, MD   +5 more
doaj   +2 more sources

Primary autoimmune myelofibrosis: a report of three cases and review of the literature [PDF]

Turkish Journal of Hematology, 2009
Myelofibrosis in association with autoimmune disorders has been consistently recognized in sporadic case reports over a number of years. Autoimmune myelofibrosis has been described most commonly in association with systemic lupus erythematosus (SLE).
Rakhee Kar, Shyamali Dutta, Seema Tyagi
doaj   +1 more source

Myelofibrosis

Blood, 2023
Abstract The clinical phenotype of primary and post–polycythemia vera and postessential thrombocythemia myelofibrosis (MF) is dominated by splenomegaly, symptomatology, a variety of blood cell alterations, and a tendency to develop vascular complications and blast phase.
Francesco Passamonti, Barbara Mora
openaire   +3 more sources

AIF1+CSF1R+ MSCs, induced by TNF‐α, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis

Hepatology, EarlyView., 2022
Mesenchymal stem cells subset, educated by TNF‐α, are involved to generate inflammatory microenvironment and promote hepatocarcinogenesis Abstract Background and Aims Increasing evidence suggests that mesenchymal stem cells (MSCs) home to injured local tissues and the tumor microenvironment in the liver.
Chen Zong, Yan Meng, Fei Ye, Xue Yang, Rong Li, Jinghua Jiang, Qiudong Zhao, Lu Gao, Zhipeng Han, Lixin Wei   +9 more
wiley   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

The management of myelofibrosis: a British Society for Haematology guideline [PDF]

, 2023
This document represents an update of the British Society for Haematology guideline on Myelofibrosis first published in 2012 and updated in 2015.1 These guidelines aim to provide healthcare professionals with clear guidance on stratified management for ...
Neelakantan, Pratap, McMullin, Mary Frances, Harrison, Claire N, Somervaille, Tim C.P., Cargo, Catherine, Green, Anna, McMullin, Mary Francis, Brady, Jessica, Garg, Mamta, Cross, Nicholas C.P., Harrison, Claire N., Khan, Alesia, Ewing, Joanne, Nangalia, Jyoti, Francis, Sebastian, McLornan, Donal P, Somervaille, Tim C P, McGregor, Andrew, Lambert, Jonathan, Butt, Nauman M, Woodley, Claire, Innes, Andrew, Psaila, Bethan, Frewin, Rebecca, Cross, Nicholas C P, Godfrey, Anna L, Mead, Adam, Mclornan, Donal P., Butt, Nauman M., Knapper, Steve, Godfrey, Anna L., Arami, Siamak, Nangalia, J., McMullin, M. F., Woodley, C., McLornan, D. P., Lambert, J., McGregor, A., Neelakantan, P., Khan, A., Arami, S., Psaila, B., Francis, S., Godfrey, A. L., Innes, A., Brady, J., Garg, M., Harrison, C. N., Butt, N. M., Ewing, J., Frewin, R., Cargo, C., Cross, N. C. P., Knapper, S., Green, A., Mead, A.   +55 more
core   +1 more source